Pfizer and Valneva are moving forward with regulatory approval for their experimental Lyme disease vaccine after it demonstrated up to 75% efficacy in late-stage trials.
The vaccine failed to meet its primary endpoint due to an unexpectedly low number of Lyme disease cases during the study, not because of safety or efficacy shortcomings.
If approved, the shot would become the first Lyme disease vaccine available in the U.S. in over two decades, filling a critical gap in tick-borne illness prevention.
In a bold move that bucks conventional drug development timelines, Pfizer and its French partner Valneva announced Monday their intention to pursue regulatory approval for their investigational Lyme disease vaccine, VLA15, even after the shot narrowly missed its primary goal in a pivotal Phase 3 study. The decision underscores a growing belief among the companies that the vaccine’s demonstrated protection outweighs the statistical complexities that clouded the trial’s final analysis.
The vaccine candidate showed robust protection in two separate efficacy analyses, achieving a 73% effectiveness rate against confirmed Lyme disease cases 28 days following the fourth dose, and approximately 75% effectiveness just one day after the final shot. Despite these promising figures, the study failed to meet its primary endpoint—a technical setback driven by a lower-than-projected number of Lyme disease infections among participants over the course of the trial, making it more difficult to achieve statistical significance. The companies maintain that the results are “clinically meaningful” and have expressed confidence in the shot’s overall profile as they prepare to file for regulatory clearance.
Lyme disease, transmitted through the bite of infected ticks, remains a pervasive public health challenge. While early-stage infections are typically treatable with antibiotics, undiagnosed or delayed cases can spiral into debilitating chronic conditions, including persistent joint pain, heart inflammation, and a post-treatment syndrome characterized by long-term brain fog and fatigue. The Centers for Disease Control and Prevention estimates that nearly half a million Americans are diagnosed with the disease annually, yet no preventive vaccine currently exists on the U.S. market.
The landscape for Lyme disease prevention has been barren since GlaxoSmithKline’s Lymerix was withdrawn in 2002, following waning demand and public scrutiny over safety concerns. That commercial failure cast a long shadow over the field, leaving Pfizer and Valneva’s candidate as the most advanced in a largely abandoned development space. With today’s announcement, the companies are signaling a strategic push to resurrect the vaccine category, banking on the potential for peak annual sales exceeding $1 billion.
Investor reaction, however, was sharply divided. While the partnership emphasized the shot’s viability and vowed to proceed with approval applications, Valneva’s shares plunged more than 35% in early trading Monday, reflecting market disappointment over the trial’s mixed outcome. Still, the decision to forge ahead positions VLA15 as a pivotal contender in what could become a new era of tick-borne disease prevention, should regulators greenlight the historic approval.
